Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by Axovant Sciences Ltd.
Information provided by (Responsible Party):
Axovant Sciences Ltd. Identifier:
First received: January 25, 2016
Last updated: March 23, 2017
Last verified: March 2017
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.

Condition Intervention Phase
Dementia With Lewy Bodies
Drug: RVT-101 35 mg
Drug: RVT-101 70 mg
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Resource links provided by NLM:

Further study details as provided by Axovant Sciences Ltd.:

Primary Outcome Measures:
  • Change from baseline on Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) [ Time Frame: 24 weeks ]
  • Change from baseline on a computerized cognitive battery [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • Change from baseline on a clinical assessment of visual hallucinations [ Time Frame: up to 24 weeks ]
  • Occurrence of reported adverse events and findings noted by investigators on clinical examination, electrocardiograms, and routine laboratory assessments [ Time Frame: 24 weeks ]

Estimated Enrollment: 240
Study Start Date: January 2016
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RVT-101 35 mg
RVT-101 35 mg once daily
Drug: RVT-101 35 mg
once daily, oral, 35-mg tablets
Experimental: RVT-101 70 mg
RVT-101 70 mg once daily
Drug: RVT-101 70 mg
once daily, oral, 35-mg tablets
Placebo Comparator: Placebo
Drug: Placebo
once daily, oral, matching tablets

Detailed Description:

The efficacy and safety of RVT-101 at doses of 70 mg and 35 mg daily will be evaluated over a 24-week double-blind treatment period in patients with dementia with Lewy bodies.

The randomization ratio will be 1:1:1 (70 mg RVT-101: 35 mg RVT-101: placebo).

Subjects completing this study will be eligible to enroll in an extension study of RVT-101 (Study RVT-101-2002).


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subject with probable DLB
  • Mini Mental State Examination (MMSE) score of 14-26 inclusive at Screening and Baseline
  • Patient has the ability to comply with procedures for cognitive and other testing in the opinion of the investigator
  • Patient has a reliable caregiver who is willing to report on the subject's status throughout the study
  • Patients currently receiving therapy for DLB are eligible for enrollment

Exclusion Criteria:

  • Atypical clinical features or clinical course that would lead the investigator to conclude primary symptoms are more likely explained by an alternate dementia diagnosis.
  • Any clinically relevant concomitant disease that, in the opinion of the investigator, makes the patient unsuitable for inclusion in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02669433

Contact: Axovant Clinical Trials; 646-677-5778

  Show 65 Study Locations
Sponsors and Collaborators
Axovant Sciences Ltd.
Study Director: Ilise Lombardo, MD Axovant Sciences Inc., Senior Vice President, Clinical Research
  More Information

Additional Information:
Responsible Party: Axovant Sciences Ltd. Identifier: NCT02669433     History of Changes
Other Study ID Numbers: RVT-101-2001
Study First Received: January 25, 2016
Last Updated: March 23, 2017

Keywords provided by Axovant Sciences Ltd.:
Dementia with Lewy bodies
Lewy bodies

Additional relevant MeSH terms:
Lewy Body Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on April 27, 2017